Inefficient ubiquitination of ligand-responsive p-6Y-EGFR mutants by p-Y371-CBL

Stable Identifier
R-HSA-1225956
Type
Reaction [transition]
Species
Homo sapiens
Compartment
plasma membrane, cytosol, extracellular region
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Inefficient ubiquitination of ligand-responsive p-6Y-EGFR mutants by p-Y371-CBL
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Phosphorylated CBL does not ubiquitinate EGFR kinase domain mutants efficiently, which enables mutant proteins to escape degradation. There are indications that phosphorylated CBL shows decreased affinity for EGFR kinase domain mutants compared to wild-type EGFR proteins, and quickly dissociates, before ubiquitination is completed. This decreased affinity may be due to altered structure of EGFR kinase domain mutants or to the presence of the chaperone protein HSP90 in complex with the mutant protein. Weaker afinity for phosphorylated CBL was directly demonstrated for EGFR L858R mutant (Yang et al. 2006), and poor ubiquitination inspite of CBL binding was shown for EGFR L858R and EGFR E746_A750del mutants (Yang et al. 2006, Padron et al. 2007). Association of HSP90 with active dimers of phospho-EGFR KD mutants negatively affects phospho-CBL-mediated ubiquitination of EGFR. Binding of HSP90 may decrease the affinity of active dimers of phospho-EGFR KD mutants for phospho-CBL, so that CBL dissociates from the complex upon phosphorylation and cannot perform ubiquitination.
Literature References
PubMed ID Title Journal Year
17699773 Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized

Padrón, D, Sato, M, Shay, JW, Gazdar, AF, Minna, JD, Roth, MG

Cancer Res 2007
16849543 Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors

Yang, S, Qu, S, Perez-Tores, M, Sawai, A, Rosen, N, Solit, DB, Arteaga, CL

Cancer Res 2006
Participants
Input
Participates
as an event of
Catalyst Activity

ubiquitin protein ligase activity of Ligand-responsive p-6Y-EGFR mutants:p-Y371-CBL [plasma membrane]

Physical Entity
Ligand-responsive p-6Y-EGFR mutants:p-Y371-CBL [plasma membrane] (Homo sapiens)
Activity
ubiquitin protein ligase activity (GO:0061630)
This event is regulated
Negatively by
Regulator
Ligand-responsive p-6Y-EGFR mutants:CBL [plasma membrane] (Homo sapiens)
Normal reaction
Ubiquitination of stimulated EGFR (CBL) (Homo sapiens)
Functional status

Loss of function of Ligand-responsive p-6Y-EGFR mutants:p-Y371-CBL [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Mondo
Authored
Orlic-Milacic, M  (2011-11-04)
Reviewed
Greulich, H  (2011-11-15)
Savas, S  (2011-11-15)
Created
Orlic-Milacic, M  (2011-03-03)
Cite Us!